Norman R Zinner

Summary

Publications

  1. ncbi Darifenacin: a muscarinic M3-selective receptor antagonist for the treatment of overactive bladder
    Norman Zinner
    Western Clinical Research, 23441 Madison Street, Suite 140, Torrance, CA 90505, USA
    Expert Opin Pharmacother 8:511-23. 2007
  2. doi Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms
    Norman R Zinner
    Western Clinical Research Inc, Torrance, California 90505, USA
    Neurourol Urodyn 30:1214-9. 2011
  3. doi Patient satisfaction with the benefits of overactive bladder treatment: exploration of influencing factors and development of a satisfaction assessment instrument
    Norman Zinner
    Western Clinical Research, Inc, Torrance, California 90505, USA
    Neurourol Urodyn 30:62-8. 2011
  4. ncbi Trospium chloride: an anticholinergic quaternary ammonium compound for the treatment of overactive bladder
    Norman R Zinner
    Western Clinical Research, 23441 Madison Street, Suite 140, Torrance, CA 90505, USA
    Expert Opin Pharmacother 6:1409-20. 2005
  5. ncbi Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder
    Norman Zinner
    Western Clinical Research, Inc, Los Angeles, California, USA
    World J Urol 23:248-52. 2005
  6. ncbi Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB
    N Zinner
    Western Clinical Research, Los Angeles, CA 90505, USA
    Int J Clin Pract 60:119-26. 2006
  7. ncbi Do food and dose timing affect the efficacy of sildenafil? A randomized placebo-controlled study
    Norman Zinner
    Western Clinical Research Inc, Torrance, CA 90505, USA
    J Sex Med 4:137-44. 2007
  8. doi Impact of solifenacin on quality of life, medical care use, work productivity, and health utility in the elderly: an exploratory subgroup analysis
    Norman Zinner
    Western Clinical Research, Inc, Torrance, California 90505, USA
    Am J Geriatr Pharmacother 7:373-82. 2009
  9. doi Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER
    Norman Zinner
    Western Clinical Research, Torrance, CA, USA
    Curr Med Res Opin 24:1583-91. 2008
  10. ncbi Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial
    Norman R Zinner
    Western Clinical Research Inc, Torrance, California, USA
    Urology 64:1177-81. 2004

Detail Information

Publications24

  1. ncbi Darifenacin: a muscarinic M3-selective receptor antagonist for the treatment of overactive bladder
    Norman Zinner
    Western Clinical Research, 23441 Madison Street, Suite 140, Torrance, CA 90505, USA
    Expert Opin Pharmacother 8:511-23. 2007
    ..On this basis, darifenacin seems to meet the standard for an effective OAB pharmacotherapy that is well-tolerated and, more importantly, minimises the risk of safety-related adverse effects...
  2. doi Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms
    Norman R Zinner
    Western Clinical Research Inc, Torrance, California 90505, USA
    Neurourol Urodyn 30:1214-9. 2011
    ..This pooled analysis of the 9-month open-label extensions to these studies evaluated the long-term efficacy and tolerability of trospium XR...
  3. doi Patient satisfaction with the benefits of overactive bladder treatment: exploration of influencing factors and development of a satisfaction assessment instrument
    Norman Zinner
    Western Clinical Research, Inc, Torrance, California 90505, USA
    Neurourol Urodyn 30:62-8. 2011
    ....
  4. ncbi Trospium chloride: an anticholinergic quaternary ammonium compound for the treatment of overactive bladder
    Norman R Zinner
    Western Clinical Research, 23441 Madison Street, Suite 140, Torrance, CA 90505, USA
    Expert Opin Pharmacother 6:1409-20. 2005
    ..The fast-acting efficacy of trospium chloride, coupled with its good safety profile and tolerability, make it an important new option for treatment of OAB...
  5. ncbi Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder
    Norman Zinner
    Western Clinical Research, Inc, Los Angeles, California, USA
    World J Urol 23:248-52. 2005
    ..Darifenacin (15 mg q.d.) provides comparable efficacy with improved tolerability versus oxybutynin (5 mg t.i.d.) in the treatment of patients with OAB...
  6. ncbi Efficacy, tolerability and safety of darifenacin, an M(3) selective receptor antagonist: an investigation of warning time in patients with OAB
    N Zinner
    Western Clinical Research, Los Angeles, CA 90505, USA
    Int J Clin Pract 60:119-26. 2006
    ..Further investigation of UFT is required to determine its role in evaluating urgency. The study confirmed that darifenacin 15 mg qd is an effective and well-tolerated treatment for OAB, which improves QoL...
  7. ncbi Do food and dose timing affect the efficacy of sildenafil? A randomized placebo-controlled study
    Norman Zinner
    Western Clinical Research Inc, Torrance, CA 90505, USA
    J Sex Med 4:137-44. 2007
    ..The clinical impact of coingestion of food and these factors has never been evaluated...
  8. doi Impact of solifenacin on quality of life, medical care use, work productivity, and health utility in the elderly: an exploratory subgroup analysis
    Norman Zinner
    Western Clinical Research, Inc, Torrance, California 90505, USA
    Am J Geriatr Pharmacother 7:373-82. 2009
    ..Overactive bladder (OAB) is a common problem among the elderly and a financial burden to society. The prevalence of OAB increases with age and affects > or = 25% of people aged > or = 65 years...
  9. doi Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER
    Norman Zinner
    Western Clinical Research, Torrance, CA, USA
    Curr Med Res Opin 24:1583-91. 2008
    ..Assess changes in resource utilization, work and activity impairment, and health utility among OAB patients continuing to have urgency symptoms with tolterodine ER 4 mg and willing to try solifenacin 5/10 mg...
  10. ncbi Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial
    Norman R Zinner
    Western Clinical Research Inc, Torrance, California, USA
    Urology 64:1177-81. 2004
    ..To investigate whether testosterone surges occur on repeat injections of 3.6 or 10.8 mg goserelin (Zoladex) depot and, if so, their extent...
  11. ncbi Pharmacotherapy for stress urinary incontinence : present and future options
    Norman R Zinner
    Western Clinical Research Inc, 23441 Madison Street, Suite 130, Torrance, CA 90505, USA
    Drugs 64:1503-16. 2004
    ..A medication such as duloxetine, if approved, would go a long way towards expanding the available treatment options for patients with SUI...
  12. ncbi Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients
    Norman R Zinner
    Doctors Urology Group, Torrance, California 90505, USA
    J Am Geriatr Soc 50:799-807. 2002
    ..To evaluate the efficacy, safety, and tolerability of a new, once-daily extended-release (ER) formulation of tolterodine in treating overactive bladder in older (> or =65) and younger (<65) patients...
  13. pmc Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy
    N Zinner
    Western Clinical Research, Inc, Torrance, CA 90505, USA
    Int J Clin Pract 62:1664-74. 2008
    ....
  14. ncbi Duloxetine: a serotonin-noradrenaline re-uptake inhibitor for the treatment of stress urinary incontinence
    Norman R Zinner
    Western Clinical Research, Inc, Torrance, CA, USA
    Expert Opin Investig Drugs 12:1559-66. 2003
    ..Adverse events were usually observed early in treatment, were mild-to-moderate in severity and were transient. Nausea was the most common reason for discontinuation...
  15. ncbi Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial
    Norman Zinner
    Department of Urology, University of California, Los Angeles, California, USA
    J Urol 171:2311-5, quiz 2435. 2004
    ..Because these qualities may provide added benefit when treating patients with symptoms associated with overactive bladder (OAB) and urge incontinence, we studied the effectiveness of trospium in treating these conditions...
  16. ncbi The overactive bladder-symptom composite score: a composite symptom score of toilet voids, urgency severity and urge urinary incontinence in patients with overactive bladder
    Norman Zinner
    Indevus Pharmaceuticals, Inc, Lexington, Massachusetts, USA
    J Urol 173:1639-43. 2005
    ..The scale has been combined with 24-hour frequency and UUI episodes to create the OAB Symptom Composite Score (OAB-SCS). We present this composite score...
  17. ncbi Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence
    Roger R Dmochowski
    Department of Urologic Surgery, Vanderbilt University, Nashville, Tennessee, USA
    J Urol 170:1259-63. 2003
    ..In this first phase 3 study we assessed the efficacy and safety of duloxetine in women with stress urinary incontinence (SUI)...
  18. ncbi Mixed urinary incontinence symptoms: urodynamic findings, incontinence severity, and treatment response
    Richard C Bump
    Lilly Research Laboratories, Indianapolis, Indiana, USA
    Obstet Gynecol 102:76-83. 2003
    ..To investigate the relationship between the symptom of mixed urinary incontinence and incontinence severity, urodynamic findings, and treatment response...
  19. ncbi Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence
    Roger R Dmochowski
    Urology Associates of North Texas, Fort Worth, Texas, USA
    J Urol 168:580-6. 2002
    ..We evaluated the efficacy and safety of an oxybutynin transdermal delivery system (TDS) in a general population of patients with overactive bladder and urge or mixed urinary incontinence...
  20. ncbi Duloxetine versus placebo in the treatment of stress urinary incontinence
    Peggy A Norton
    Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, USA
    Am J Obstet Gynecol 187:40-8. 2002
    ..The purpose of this study was to assess the efficacy and safety of duloxetine, a selective inhibitor of serotonin and norepinephrine reuptake, in the treatment of stress urinary incontinence...
  21. ncbi Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence
    Roger R Dmochowski
    Department of Urology, Vanderbilt University, Nashville, Tennessee, USA
    Urology 62:237-42. 2003
    ..To compare the efficacy and safety of an oxybutynin transdermal delivery system (OXY-TDS) and oral, long-acting tolterodine (TOL-LA) with placebo in previously treated patients with urge or mixed urinary incontinence...
  22. doi Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study
    Roger R Dmochowski
    Department of Urology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    Urology 71:449-54. 2008
    ..This randomized controlled trial evaluated the efficacy and tolerability of this new extended-release formulation, trospium chloride 60 mg QD...
  23. ncbi Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer
    Matthew R Smith
    Massachusetts General Hospital, Cox 640, 100 Blossom St, Boston, MA 02114, USA
    J Clin Oncol 23:2918-25. 2005
    ..To describe the natural history of nonmetastatic prostate cancer and rising prostate-specific antigen (PSA) despite androgen deprivation therapy...
  24. ncbi Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies
    Werner Schäfer
    International Continence Society Office, Southme Hospital, Bristol, BSIO 5NB, United Kingdom
    Neurourol Urodyn 21:261-74. 2002
    ..This does not imply that this technique is the only one possible. Rather, it means that this technique is well-established, and gives good results when used with the suggested standards of good urodynamic practice...